Bracketing approach for multiple strenght product EMA [Regulatives / Guidelines]

posted by jag009  – NJ, 2021-07-06 21:19 (1254 d 16:13 ago) – Posting: # 22462
Views: 2,214

Hi all,

For drug product which have multiple strengths (lets say 3), my thinking is to run a BE study comparing highest and lowest strength, and present dissolution similarities between the three strengths + a formulation composition table showing that the formulations are proportional.

Question: What if the product release > 85% within 15 mins? If so then one can't use dissolution to demonstrate similarity.

The product is BCS class 2.

Thx

J

Complete thread:

UA Flag
Activity
 Admin contact
23,336 posts in 4,902 threads, 1,667 registered users;
29 visitors (0 registered, 29 guests [including 6 identified bots]).
Forum time: 12:32 CET (Europe/Vienna)

Biostatistician. One who has neither the intellect for mathematics
nor the commitment for medicine but likes to dabble in both.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5